NovaBridge Biosciences (NBP) NASDAQ
2.60
+0.06(+2.36%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.60
+0.06(+2.36%)
Currency In USD
| Previous Close | 2.54 |
| Open | 2.57 |
| Day High | 2.62 |
| Day Low | 2.55 |
| 52-Week High | 6.79 |
| 52-Week Low | 0.8 |
| Volume | 740,892 |
| Average Volume | 761,511 |
| Market Cap | 299.69M |
| PE | -5.42 |
| EPS | -0.48 |
| Moving Average 50 Days | 2.99 |
| Moving Average 200 Days | 3.66 |
| Change | 0.06 |
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMDVIS-101 demonstrated mean
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
GlobeNewswire Inc.
Mar 03, 2026 2:05 PM GMT
VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO Visara, a NovaBridge Majority-Own
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 12:00 PM GMT
ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that NovaBridge’s